Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments

D. M. Goldenberg, T. J. Wlodkowski, R. M. Sharkey, E. B. Silberstein, Aldo N Serafini, I. I. Garty, R. L. Van Heertum, E. A. Higginbotham-Ford, J. A. Kotler, N. Balasubramanian, L. C. Swayne, H. J. Hansen, C. M. Pinsky

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

This prospective, randomized multicenter study in 62 patients was designed to evaluate the efficacy and safety of radioimmunodetection (RAID) with 123I-labeled fragments, F(ab')2 and Fab', of IMMU-4, an anti-CEA monoclonal antibody (Immu-RAID-CEA). It was found that ImmuRAID-CEA was safe and disclosed colorectal cancer sites at least 1 cm in size. The positive predictive value by lesions was 77% initially, and increased to 91% after 7 mo of follow-up. Only one patient developed a low level of HAMA. In 17 patients with 32 surgically confirmed lesions, there were 9% true-positive lesions for CT when RAID was false-negative, and 22% for RAID when CT was false-negative. Either CT or RAID detected all 32 lesions. In this small series, therefore, RAID was shown to complement CT findings by confirming suspected tumors and disclosing new lesions which had previously been occult.

Original languageEnglish
Pages (from-to)61-70
Number of pages10
JournalJournal of Nuclear Medicine
Volume34
Issue number1
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Radioimmunodetection
Immunoglobulin Fragments
Iodine
Colorectal Neoplasms
Monoclonal Antibodies
Multicenter Studies
Safety

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Goldenberg, D. M., Wlodkowski, T. J., Sharkey, R. M., Silberstein, E. B., Serafini, A. N., Garty, I. I., ... Pinsky, C. M. (1993). Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. Journal of Nuclear Medicine, 34(1), 61-70.

Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. / Goldenberg, D. M.; Wlodkowski, T. J.; Sharkey, R. M.; Silberstein, E. B.; Serafini, Aldo N; Garty, I. I.; Van Heertum, R. L.; Higginbotham-Ford, E. A.; Kotler, J. A.; Balasubramanian, N.; Swayne, L. C.; Hansen, H. J.; Pinsky, C. M.

In: Journal of Nuclear Medicine, Vol. 34, No. 1, 01.01.1993, p. 61-70.

Research output: Contribution to journalArticle

Goldenberg, DM, Wlodkowski, TJ, Sharkey, RM, Silberstein, EB, Serafini, AN, Garty, II, Van Heertum, RL, Higginbotham-Ford, EA, Kotler, JA, Balasubramanian, N, Swayne, LC, Hansen, HJ & Pinsky, CM 1993, 'Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments', Journal of Nuclear Medicine, vol. 34, no. 1, pp. 61-70.
Goldenberg DM, Wlodkowski TJ, Sharkey RM, Silberstein EB, Serafini AN, Garty II et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. Journal of Nuclear Medicine. 1993 Jan 1;34(1):61-70.
Goldenberg, D. M. ; Wlodkowski, T. J. ; Sharkey, R. M. ; Silberstein, E. B. ; Serafini, Aldo N ; Garty, I. I. ; Van Heertum, R. L. ; Higginbotham-Ford, E. A. ; Kotler, J. A. ; Balasubramanian, N. ; Swayne, L. C. ; Hansen, H. J. ; Pinsky, C. M. / Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. In: Journal of Nuclear Medicine. 1993 ; Vol. 34, No. 1. pp. 61-70.
@article{b0e7a5aee5064f3c84010545ed8bfb5c,
title = "Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments",
abstract = "This prospective, randomized multicenter study in 62 patients was designed to evaluate the efficacy and safety of radioimmunodetection (RAID) with 123I-labeled fragments, F(ab')2 and Fab', of IMMU-4, an anti-CEA monoclonal antibody (Immu-RAID-CEA). It was found that ImmuRAID-CEA was safe and disclosed colorectal cancer sites at least 1 cm in size. The positive predictive value by lesions was 77{\%} initially, and increased to 91{\%} after 7 mo of follow-up. Only one patient developed a low level of HAMA. In 17 patients with 32 surgically confirmed lesions, there were 9{\%} true-positive lesions for CT when RAID was false-negative, and 22{\%} for RAID when CT was false-negative. Either CT or RAID detected all 32 lesions. In this small series, therefore, RAID was shown to complement CT findings by confirming suspected tumors and disclosing new lesions which had previously been occult.",
author = "Goldenberg, {D. M.} and Wlodkowski, {T. J.} and Sharkey, {R. M.} and Silberstein, {E. B.} and Serafini, {Aldo N} and Garty, {I. I.} and {Van Heertum}, {R. L.} and Higginbotham-Ford, {E. A.} and Kotler, {J. A.} and N. Balasubramanian and Swayne, {L. C.} and Hansen, {H. J.} and Pinsky, {C. M.}",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "61--70",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments

AU - Goldenberg, D. M.

AU - Wlodkowski, T. J.

AU - Sharkey, R. M.

AU - Silberstein, E. B.

AU - Serafini, Aldo N

AU - Garty, I. I.

AU - Van Heertum, R. L.

AU - Higginbotham-Ford, E. A.

AU - Kotler, J. A.

AU - Balasubramanian, N.

AU - Swayne, L. C.

AU - Hansen, H. J.

AU - Pinsky, C. M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - This prospective, randomized multicenter study in 62 patients was designed to evaluate the efficacy and safety of radioimmunodetection (RAID) with 123I-labeled fragments, F(ab')2 and Fab', of IMMU-4, an anti-CEA monoclonal antibody (Immu-RAID-CEA). It was found that ImmuRAID-CEA was safe and disclosed colorectal cancer sites at least 1 cm in size. The positive predictive value by lesions was 77% initially, and increased to 91% after 7 mo of follow-up. Only one patient developed a low level of HAMA. In 17 patients with 32 surgically confirmed lesions, there were 9% true-positive lesions for CT when RAID was false-negative, and 22% for RAID when CT was false-negative. Either CT or RAID detected all 32 lesions. In this small series, therefore, RAID was shown to complement CT findings by confirming suspected tumors and disclosing new lesions which had previously been occult.

AB - This prospective, randomized multicenter study in 62 patients was designed to evaluate the efficacy and safety of radioimmunodetection (RAID) with 123I-labeled fragments, F(ab')2 and Fab', of IMMU-4, an anti-CEA monoclonal antibody (Immu-RAID-CEA). It was found that ImmuRAID-CEA was safe and disclosed colorectal cancer sites at least 1 cm in size. The positive predictive value by lesions was 77% initially, and increased to 91% after 7 mo of follow-up. Only one patient developed a low level of HAMA. In 17 patients with 32 surgically confirmed lesions, there were 9% true-positive lesions for CT when RAID was false-negative, and 22% for RAID when CT was false-negative. Either CT or RAID detected all 32 lesions. In this small series, therefore, RAID was shown to complement CT findings by confirming suspected tumors and disclosing new lesions which had previously been occult.

UR - http://www.scopus.com/inward/record.url?scp=0027391734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027391734&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 61

EP - 70

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -